Topics

Engineering Immune Response With In-Situ Vaccines in iNHL

09:57 EDT 26 Mar 2020 | OncLive

Joshua Brody, MD, discusses research with in-situ vaccination in non-Hodgkin lymphoma and strategies being developed to overcome acquired resistance.

Original Article: Engineering Immune Response With In-Situ Vaccines in iNHL

NEXT ARTICLE

More From BioPortfolio on "Engineering Immune Response With In-Situ Vaccines in iNHL"

Quick Search

Relevant Topics

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Hodgkin lymphoma
Hodgkin Lymphoma is a  disorder caused by malignant proliferation of lymphocytes, which contain characteristic mirror-image nuclei (Reed-Sternburg cells). The resulting lymphadenopathy can be limited to a single lymph node region (Stage 1) or spread...